DelveInsight’s, “Acute Ischemic Stroke Pipeline Insight, 2023,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in the Acute Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Acute Ischemic Stroke pipeline products in this space.
For Acute Ischemic Stroke Emerging drugs, the Acute Ischemic Stroke pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Acute Ischemic Stroke pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Acute Ischemic Stroke Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Acute Ischemic Stroke clinical trials studies, Acute Ischemic Stroke NDA approvals (if any), and product development activities comprising the technology, Acute Ischemic Stroke collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Acute Ischemic Stroke Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Acute Ischemic Stroke Pipeline landscape @ Acute Ischemic Stroke Pipeline Outlook Report
Acute Ischemic Stroke Overview
Acute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, which results in damage to brain cells. Acute ischemic stroke is a leading cause of death and disability in the US and affects approximately 7, 00,000 people each year. Signs and symptoms of stroke may include sudden-onset numbness or weakness in an arm or leg, facial droop, difficulty speaking or understanding speech, confusion, trouble with balance or coordination, and loss of vision.
Acute Ischemic Stroke Emerging Drugs Profile
Nelonemdaz is a moderate NR2B-selective N-methyl d-aspartate (NMDA) receptor antagonist and potent spin trapper that reduces NMDA receptor-mediated excitotoxicity and oxidative stress, two major routes of brain cell death leading to disability and death after stroke. Nelonemdaz previously showed better efficacy and a longer therapeutic time window than subtype-unselective NMDA antagonists or antioxidants alone in 5 animal models of stroke. Its safety and tolerability in humans has been established in two earlier phase I studies conducted in 165 healthy young and elderly volunteers in the US and China.
Tenecteplase (TNKase, TNK-tPA or TNK) is a thrombolytic agent derived from the tissue plasminogen activator (tPA), that binds fibrin and converts plasminogen to plasmin. It is a 527-amino acid glycoprotein developed by replacing three amino acids at the T, N and K positions of the glycoprotein structure of tPA under genetic recombinant technology. After replacing threonine 103 with asparagine, asparagine 117 with glutamine and a tetra-alanine at amino acids 296–299, TNK is about eightfold more potent in dissolving clot, 80-fold higher resistance to plasminogen activator inhibitor-1 and 14-fold enhanced relative fibrin specificity, and with a longer half-life (20 min).Hence, TNK is administered as a single intravenous bolus. Tenecteplase has a well-characterized mechanism of action with important practical advantages in administration and superior clinical efficacy for patients with large-vessel occlusion. It is currently being evaluated in imaging-eligible, late-window acute ischemic stroke (AIS) patients.
SP-8203, under development, is a new neuroprotective compound for acute ischemic stroke. It is a quinazoline-2, 4-dione derivative with multiple potent neuroprotective mechanisms of action including anti-inflammatory activities. Patent applications have been filed in 52 countries and granted in 44 countries. SP-8203, has proved as a first-in-class candidate which has a multiple neuroprotective effects through a variety of the stroke animal models. Particularly, because it extends the therapeutic window when combined with tPA, more patients would have the benefit of reducing cerebral infarction and edema as well as hemorrhage and mortality. In fact, a few years following by the project outset, SP-8203 won the top 10 future pharmaceutical special projects run by the Ministry of Health and Welfare, because it was highly evaluated for its distinctiveness. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Acute Ischemic Stroke.
NoNO-SC is a subcutaneously injectable nerinetide analog for the treatment of all strokes. Autoinjector compatibility (i.e. a “stroke pen”) enables administration by any caregiver at home, en route to the hospital or upon arrival in the emergency department. Currently, the drug is in Preclinical stage of Clinical trial evaluation for the treatment of Acute Ischemic Stroke.
For further information, refer to the detailed Acute Ischemic Stroke Drugs Launch, Acute Ischemic Stroke Developmental Activities, and Acute Ischemic Stroke News, click here for Acute Ischemic Stroke Ongoing Clinical Trial Analysis
Acute Ischemic Stroke Pipeline Therapeutics Analysis
There are approx. 35+ key Acute Ischemic Stroke companies which are developing the Acute Ischemic Stroke therapies. The companies which have their Acute Ischemic Stroke drug candidates in the most advanced stage, i.e. phase III include, GNT Pharma.
Acute Ischemic Stroke Pipeline Segmentation
Phases
Route of Administration
Molecule Type
Find out more about the Acute Ischemic Stroke Pipeline Segmentation, Therapeutics Assessment, and Acute Ischemic Stroke Emerging Drugs @ Acute Ischemic Stroke Treatment Landscape
Scope of the Acute Ischemic Stroke Pipeline Report
Dive deep into rich insights for drugs for Acute Ischemic Stroke Pipeline Companies and Therapies, click here @ Acute Ischemic Stroke Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Acute Ischemic Stroke Mergers and acquisitions, Acute Ischemic Stroke Licensing Activities @ Acute Ischemic Stroke Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/